Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bassel Sayegh

Internal Medicine Pittsburgh, PA Medical Doctor

NPI 1568711000 CMS profile 806579

320 E North Ave, 4 Snyder Pavilion, Pittsburgh, PA 15212

Open in the dashboard

General payments

$76,929

305 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bassel Sayegh of Pittsburgh, PA is reported in the CMS Open Payments database as having received $76,929 across 305 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,163 21
2024 General $3,635 13
2023 General $12,428 56
2022 General $18,894 77
2021 General $4,115 48
2020 General $4,834 39
2019 General $31,858 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bassel Sayegh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bassel Sayegh were reported at $1,163. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bassel Sayegh Internal Medicine median Middle half National median
2019 $31,858 $159 $48–$570 $163
2020 $4,834 $119 $33–$402 $114
2021 $4,115 $135 $37–$521 $132
2022 $18,894 $141 $42–$496 $149
2023 $12,428 $149 $45–$519 $160
2024 $3,635 $154 $47–$537 $164
2025 $1,163 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $33,338 166 payments
  2. Medtronic Vascular, Inc. $27,896 27 payments
  3. Medtronic, Inc. $9,174 47 payments
  4. Atricure, Inc. $2,104 12 payments
  5. Abbott Laboratories $1,357 19 payments
  6. Biosense Webster, Inc. $896 10 payments
  7. Medical Device Business Services, Inc. $597 1 payment
  8. Baylis Medical Company Inc $491 4 payments
  9. iRhythm Technologies, Inc. $454 7 payments
  10. AstraZeneca Pharmaceuticals LP $261 3 payments
  11. Other $362 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $27,953 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,025 8 payments
  3. Food and Beverage $15,495 248 payments
  4. Travel and Lodging $10,709 39 payments
  5. Consulting Fee $3,000 1 payment
  6. Education $746 5 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $16,610 30 payments
  2. WATCHMAN Structural Heart $3,919 47 payments
  3. General - Therapies $3,109 2 payments
  4. Rhythmia Mapping System $1,429 8 payments
  5. GENERAL - BRADY $1,257 1 payment
  6. SYNERGY ABLATION SYSTEM $1,209 3 payments
  7. GENERAL EP $1,108 1 payment
  8. WATCHMAN Pain Management $1,060 16 payments
  9. General - Vascular Access $1,058 4 payments
  10. CARDIOBLATE CRYOFLEX $1,002 8 payments
  11. Other $12,802 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

228

Median for Internal Medicine: 777

Drug cost

$43,023

Median for Internal Medicine: $73,373

Branded share of claims

37.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 49 $39,857
Metoprolol Succinate Generic 58 $1,380
Amiodarone Hcl Generic 60 $788
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 13 $355
Metoprolol Tartrate Generic 24 $341
Sotalol Sotalol Hcl Brand 12 $187
Clopidogrel Clopidogrel Bisulfate Brand 12 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$107,549

Medicare's payments for the services billed

Medicare patients

630

Average age 77

Services billed

1,807

244 women, 386 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Ischemic heart disease 61%
Heart failure 56%
Arthritis 51%
Chronic kidney disease 42%
Diabetes 41%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record